UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2014

ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
  
000-52446
  
88-0378336
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)

501 Fifth Avenue, 3rd Floor
New York, NY
  
10017
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (646) 459-4201

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
 
 
 
 
 
Item 8.01 Other Events.
 
Actinium Pharmaceuticals, Inc. (the "Company") issued a press release on June 24, 2014 announcing a proposed public offering of its common stock. A copy of the release is attached to this Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.  
 
Exhibit 99.1
  
Press release of Actinium Pharmaceuticals, Inc. dated June 24, 2014
 
 
2
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 24, 2014
ACTINIUM PHARMACEUTICALS, INC.
  
       
 
By:
/s/ Kaushik J. Dave 
  
   
Name:  Kaushik J. Dave
Title:    President and Chief Executive
             Officer
  
 
3